An Overview of Diagnostic and Management Strategies for Talaromycosis, an Underrated Disease

Underrated and neglected, talaromycosis is a life-threatening fungal disease endemic to the tropical and subtropical regions of Asia. In China, it has been reported that talaromycosis mortality doubles from 24 to 50% when the diagnosis is delayed, and reaches 100% when the diagnosis is missed. Thus, the accurate diagnosis of talaromycosis is of utmost importance. Herein, in the first part of this article, we provide an extensive review of the diagnostic tools used thus far by physicians in the management of cases of talaromycosis. The challenges encountered and the perspectives which may aid in the discovery of more accurate and reliable diagnostic approaches are also discussed. In the second part of this review, we discuss the drugs used to prevent and treat T. marneffei infection. Alternative therapeutic options and potential drug resistance reported in the contemporary literature are also discussed. We aim to guide researchers towards the discovery of novel approaches to prevent, diagnose, and treat talaromycosis, and therefore improve the prognosis for those afflicted by this important disease.

[1]  Dustin L. Stwalley,et al.  Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease , 2023, Crohn's & colitis 360.

[2]  Runhua Han,et al.  An Overlooked and Underrated Endemic Mycosis—Talaromycosis and the Pathogenic Fungus Talaromyces marneffei , 2023, Clinical microbiology reviews.

[3]  Jinqiao Sun,et al.  Rapid diagnosis of Talaromyces marneffei infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity , 2022, Frontiers in Cellular and Infection Microbiology.

[4]  Jian Guo,et al.  MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China) , 2022, Infection and drug resistance.

[5]  Yaokai Chen,et al.  Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China , 2022, Infectious Diseases and Therapy.

[6]  Qing Wu,et al.  Diagnostic performance of the metagenomic next-generation sequencing in lung biopsy tissues in patients suspected of having a local pulmonary infection , 2022, BMC Pulmonary Medicine.

[7]  J. C. Hoving,et al.  Key thermally dimorphic fungal pathogens: shaping host immunity , 2022, Open Biology.

[8]  Zheng-tu Li,et al.  Talaromyces marneffei and Mycobacterium tuberculosis co-infection in a patient with high titer anti-interferon-γ autoantibodies: a case report , 2022, BMC Infectious Diseases.

[9]  Yu Qin,et al.  HIV-associated talaromycosis: does timing of antiretroviral therapy matter༟. , 2021, The Journal of infection.

[10]  K. Deng,et al.  Environmental Risk Factors for Talaromycosis Hospitalizations of HIV-Infected Patients in Guangzhou, China: Case Crossover Study , 2021, Frontiers in Medicine.

[11]  J. Chan,et al.  A global call for talaromycosis to be recognised as a neglected tropical disease. , 2021, The Lancet. Global health.

[12]  Y. Qiu,et al.  Talaromyces marneffei and nontuberculous mycobacteria co-infection in HIV-negative patients , 2021, Scientific Reports.

[13]  P. Woo,et al.  Rapid Genomic Diagnosis of Fungal Infections in the Age of Next-Generation Sequencing , 2021, Journal of fungi.

[14]  A. Kaltsas,et al.  An inexpensive point-of-care immunochromatographic test for Talaromyces marneffei infection based on the yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin , 2021, PLoS neglected tropical diseases.

[15]  Y. Wen,et al.  Gastrointestinal manifestations of Talaromyces marneffei infection in an HIV-infected patient rapidly verified by metagenomic next-generation sequencing: a case report , 2021, BMC Infectious Diseases.

[16]  S. Seyedmousavi,et al.  Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei , 2021, Antimicrobial Agents and Chemotherapy.

[17]  S. Roytrakul,et al.  Antifungal Properties of Protein Extracts from Thai Medicinal Plants to Opportunistic Fungal Pathogens , 2021, Walailak Journal of Science and Technology (WJST).

[18]  Jianning Jiang,et al.  Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study , 2021, Mycopathologia.

[19]  Yaokai Chen,et al.  Independent Risk Factors for Deaths due to AIDS in Chongqing, China: Does Age Matter? , 2021, Frontiers in Medicine.

[20]  M. Kruk,et al.  Considerations for a sustainability framework for neglected tropical diseases programming , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  Wenhong Zhang,et al.  Improving Pulmonary Infection Diagnosis with Metagenomic Next Generation Sequencing , 2021, Frontiers in Cellular and Infection Microbiology.

[22]  T. Le,et al.  Talaromyces marneffei promotes M2-like polarization of human macrophages by downregulating SOCS3 expression and activating the TLR9 pathway , 2021, Virulence.

[23]  X. Ou,et al.  Clinical epidemiology and outcome of HIV‐associated talaromycosis in Guangdong, China, during 2011–2017 , 2020, HIV medicine.

[24]  A. Andrianopoulos,et al.  Antifungal Activity and Molecular Mechanisms of Partial Purified Antifungal Proteins from Rhinacanthus nasutus against Talaromyces marneffei , 2020, Journal of fungi.

[25]  A. Chughtai,et al.  Case Report: Successful Treatment of Pulmonary Talaromyces marneffei Infection with Posaconazole in a Renal Transplant Recipient. , 2020, The American journal of tropical medicine and hygiene.

[26]  Yaokai Chen,et al.  Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV‐infected patients with talaromycosis , 2020, Mycoses.

[27]  J. Chan,et al.  Occult Talaromyces marneffei Infection Unveiled by the Novel Mp1p Antigen Detection Assay , 2020, Open forum infectious diseases.

[28]  S. Phongpaichit,et al.  Antifungal activity of marine‐derived actinomycetes against Talaromyces marneffei , 2020, Journal of applied microbiology.

[29]  E. Ashley,et al.  Is stopping secondary prophylaxis safe in HIV‐positive talaromycosis patients? Experience from Myanmar , 2020, HIV Medicine.

[30]  N. P. H. Lan,et al.  Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Jianping Xu,et al.  Rapid and precise diagnosis of T. marneffei pulmonary infection in a HIV-negative patient with autosomal-dominant STAT3 mutation: a case report , 2020, Therapeutic advances in respiratory disease.

[32]  Annapoorna Singh,et al.  Localized Talaromyces marneffei infection presenting as a tonsillar mass mimicking malignancy , 2020, IDCases.

[33]  S. Kajiwara,et al.  Identification and functional characterization of Penicillium marneffei major facilitator superfamily (MFS) transporters , 2020, Bioscience, biotechnology, and biochemistry.

[34]  K. Gough,et al.  Talaromyces marneffei fungemia after travel to China in a Canadian patient with AIDS , 2020, Canadian Medical Association Journal.

[35]  Tao Chen,et al.  Predictive models for Talaromyces marneffei infection in HIV-infected patients using routinely collected data , 2020 .

[36]  A. Andrianopoulos Laboratory Maintenance and Growth of Talaromyces marneffei , 2020, Current protocols in microbiology.

[37]  K. Ratanabanangkoon,et al.  Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing. , 2019, Diagnostic microbiology and infectious disease.

[38]  L. Xi,et al.  Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen , 2019, Mycopathologia.

[39]  Yuanlin Guan,et al.  Progressive Multifocal Leukoencephalopathy Diagnosed by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid in an HIV Patient , 2019, Front. Neurol..

[40]  Susu He,et al.  Concurrent infection with Talaromyces marneffei and Cryptococcus neoformans in a patient without HIV infection , 2019, Experimental and therapeutic medicine.

[41]  M. Aguilar,et al.  Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications , 2019, International journal of molecular sciences.

[42]  Y. Lau,et al.  Application of Flow Cytometry in the Diagnostics Pipeline of Primary Immunodeficiencies Underlying Disseminated Talaromyces marneffei Infection in HIV-Negative Children , 2019, Front. Immunol..

[43]  Linlin Li,et al.  Characterization of Clinical Isolates of Talaromyces marneffei and Related Species, California, USA , 2019, Emerging infectious diseases.

[44]  Jianhua Hou,et al.  Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis , 2019, BMC Infectious Diseases.

[45]  M. Loebinger,et al.  Nontuberculous Mycobacterial Pulmonary Disease , 2015 .

[46]  S. Butler-Wu,et al.  The Brief Case: Pneumonia Caused by Talaromyces marneffei , 2019, Journal of Clinical Microbiology.

[47]  Hong Luo,et al.  Evaluation of in vitro antifungal activity of osthole against Talaromyces marneffei in yeast phase , 2019 .

[48]  Y. Ruan,et al.  Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[49]  A. Andrianopoulos,et al.  A unique aspartyl protease gene expansion in Talaromyces marneffei plays a role in growth inside host phagocytes , 2019, Virulence.

[50]  E. Nehl,et al.  Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study , 2019, Emerging microbes & infections.

[51]  Achala R. Rathnayaka,et al.  The world’s ten most feared fungi , 2018, Fungal Diversity.

[52]  L. Ye,et al.  Accuracy of rapid diagnosis of Talaromyces marneffei: A systematic review and meta-analysis , 2018, PloS one.

[53]  F. Hu,et al.  Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[54]  A. Arroliga,et al.  Talaromyces marneffei infection in a non-HIV non-endemic population , 2018, IDCases.

[55]  Liangxing Wang,et al.  Fungemia caused by Penicillium marneffei in an immunocompetent patient with COPD , 2018, Medicine.

[56]  C. Cooper,et al.  Adaptation to macrophage killing by Talaromyces marneffei , 2017, Future science OA.

[57]  J. Farrar,et al.  A Trial of Itraconazole or Amphotericin B for HIV‐Associated Talaromycosis , 2017, The New England journal of medicine.

[58]  Pingli Wang,et al.  Acute Disseminated Talaromyces marneffei in An Immunocompetent Patient , 2017, Mycopathologia.

[59]  Robert Schlaberg,et al.  Validation of Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection. , 2017, Archives of pathology & laboratory medicine.

[60]  Cunwei Cao,et al.  Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study , 2017, Mycopathologia.

[61]  M. Slater,et al.  F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase , 2016, Proceedings of the National Academy of Sciences.

[62]  N. Tachikawa,et al.  Penicillium marneffei Infection with β-D-glucan Elevation: A Case Report and Literature Review. , 2016, Internal medicine.

[63]  N. P. H. Lan,et al.  Development and evaluation of a real‐time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma , 2016, Mycoses.

[64]  J. Jarvis,et al.  HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings , 2016, Current Clinical Microbiology Reports.

[65]  J. Nosanchuk,et al.  A novel inhibition ELISA for the detection and monitoring of Penicillium marneffei antigen in human serum , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[66]  T. Proft,et al.  Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing , 2016, Virulence.

[67]  P. Woo,et al.  Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients , 2016, Emerging Microbes & Infections.

[68]  G. Weinstock,et al.  Making the Leap from Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in Infectious Disease Diagnostics , 2015, mBio.

[69]  L. Bekker,et al.  Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  J. Perfect,et al.  Live Imaging of Host-Parasite Interactions in a Zebrafish Infection Model Reveals Cryptococcal Determinants of Virulence and Central Nervous System Invasion , 2015, mBio.

[71]  Ho Yee Cheung,et al.  Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine , 2015, Evidence-based complementary and alternative medicine : eCAM.

[72]  Hong-ru Li,et al.  Diffuse interstitial and multiple cavitary lung lesions due to Talaromyces marneffei infection in a non-HIV patient , 2015, New microbes and new infections.

[73]  L. Ye,et al.  Single Use of Itraconazole Has No Effect on Treatment for Penicillium Marneffei with HIV Infection. , 2015, Archives of Iranian medicine.

[74]  J. Wrobel,et al.  Penicillium marneffei infection in a lung transplant recipient , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[75]  Lingyan Qin,et al.  A novel method of combining Periodic Acid Schiff staining with Wright-Giemsa staining to identify the pathogens Penicillium marneffei, Histoplasma capsulatum, Mucor and Leishmania donovani in bone marrow smears. , 2015, Experimental and therapeutic medicine.

[76]  C. Liao,et al.  Disseminated Penicillium marneffei mimicking paradoxical response and relapse in a non-HIV patient with pulmonary tuberculosis. , 2015, Journal of the Chinese Medical Association : JCMA.

[77]  M. Strobel,et al.  Penicilliosis and AIDS in Haiphong, Vietnam: evolution and predictive factors of death. , 2014, Medecine et maladies infectieuses.

[78]  J. Frisvad,et al.  Polyphasic taxonomy of the genus Talaromyces , 2014, Studies in mycology.

[79]  M. Cuenca‐Estrella Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[80]  J. Eickhoff,et al.  Distinct Innate Immune Phagocyte Responses to Aspergillus fumigatus Conidia and Hyphae in Zebrafish Larvae , 2014, Eukaryotic Cell.

[81]  R. Chaiwarith,et al.  Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study , 2013, BMC Infectious Diseases.

[82]  S. Lawn,et al.  Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa , 2013, PloS one.

[83]  M. Bronze,et al.  Clinical use of anti-TNF therapy and increased risk of infections , 2013, Drug, healthcare and patient safety.

[84]  Yung-Jen Chuang,et al.  Identification of Infection- and Defense-Related Genes via a Dynamic Host-Pathogen Interaction Network Using a Candida Albicans-Zebrafish Infection Model , 2013, Journal of Innate Immunity.

[85]  L. Xi,et al.  Penicillium marneffei Infection: An Emerging Disease in Mainland China , 2013, Mycopathologia.

[86]  D. Boulware,et al.  Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  P. Horby,et al.  Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam , 2012, AIDS Research and Therapy.

[88]  J. Hart,et al.  Travel‐related disseminated Penicillium marneffei infection in a renal transplant patient , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[89]  T. Horii,et al.  E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis , 2011, Antimicrobial Agents and Chemotherapy.

[90]  G. S. de Hoog,et al.  Molecular identification of Penicillium marneffei using rolling circle amplification , 2011, Mycoses.

[91]  N. P. H. Lan,et al.  Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[92]  M. Falagas,et al.  β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[93]  V. Wahn,et al.  Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. , 2011, Blood.

[94]  P. Massip,et al.  [Penicilliosis in Vietnam: a series of 94 patients]. , 2010, La Revue de medecine interne.

[95]  C. Shikuma,et al.  AIDS‐associated Cryptococcus neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resource‐limited settings. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  C. Ki,et al.  [A case of disseminated Penicillium marneffei infection in a liver transplant recipient]. , 2010, The Korean journal of laboratory medicine.

[97]  O. Tsang,et al.  Disseminated Penicilliosis, Recurrent Bacteremic Nontyphoidal Salmonellosis, and Burkholderiosis Associated with Acquired Immunodeficiency Due to Autoantibody against Gamma Interferon , 2010, Clinical and Vaccine Immunology.

[98]  T. Sirisanthana,et al.  Application of nested PCR to detect Penicillium marneffei in serum samples. , 2009, Medical mycology.

[99]  John T Brooks,et al.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[100]  Xiao-hong Wang,et al.  The effects of temperature, pH, and salinity on the growth and dimorphism of Penicillium marneffei. , 2007, Medical mycology.

[101]  Hsin-Yun Sun,et al.  Detection of Circulating Galactomannan in Serum Samples for Diagnosis of Penicillium marneffei Infection and Cryptococcosis among Patients Infected with Human Immunodeficiency Virus , 2007, Journal of Clinical Microbiology.

[102]  Michael G. Vann,et al.  In Vitro Antifungal-Drug Susceptibilities of Mycelial and Yeast Forms of Penicillium marneffei Isolates in Cambodia , 2006, Journal of Clinical Microbiology.

[103]  S. Antinori,et al.  Disseminated Penicillium marneffei infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. , 2006, Journal of travel medicine.

[104]  S. Tanprawate,et al.  A 12-case series of Penicillium marneffei pneumonia. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[105]  T. Sirisanthana,et al.  Penicillium marneffei Infection and Recent Advances in the Epidemiology and Molecular Biology Aspects , 2006, Clinical Microbiology Reviews.

[106]  E. Tacconelli,et al.  Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. , 2004, FEMS immunology and medical microbiology.

[107]  M. Senba,et al.  Clinicopathologic study of hepatic Penicillium marneffei in Northern Thailand. , 2004, Archives of pathology & laboratory medicine.

[108]  K. Nishimura,et al.  In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi: Comparison of Yeast-Like and Mycelial Forms , 2003, Antimicrobial Agents and Chemotherapy.

[109]  A. Chakrabarti,et al.  Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. , 2002, The Journal of infection.

[110]  K. Nelson,et al.  A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[111]  K. Yuen,et al.  Biotyping of Penicillium marneffeiReveals Concentration-Dependent Growth Inhibition by Galactose , 2001, Journal of Clinical Microbiology.

[112]  K. Tintelnot,et al.  Disseminated Penicillium marneffei infection in an African AIDS patient. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[113]  K. Yuen,et al.  Detection of Specific Antibodies to an Antigenic Mannoprotein for Diagnosis of Penicillium marneffeiPenicilliosis , 1998, Journal of Clinical Microbiology.

[114]  K. Nelson,et al.  Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[115]  K. Nelson,et al.  Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[116]  C. H. Lee,et al.  Atypical manifestations in a patient with systemic lupus erythematosus. , 1997, Journal of clinical pathology.

[117]  K. Nelson,et al.  Disseminated Penicillium marneffei infection in Southeast Asia , 1994, The Lancet.

[118]  T. Sirisanthana,et al.  An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. , 1992, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[119]  G. Piérard,et al.  IMMUNOHISTOCHEMICAL IDENTIFICATION OF PENICILLIUM MARNEFFEI BY MONOCLONAL ANTIBODY , 1992, International journal of dermatology.

[120]  D. Tsang,et al.  Disseminated Penicillium marneffei infection in HIV‐infected subject , 1992, Histopathology.

[121]  Y. Chan,et al.  Ultrastructural observations on Penicillium marneffei in natural human infection. , 1990, Ultrastructural pathology.

[122]  L. Ajello,et al.  Infection caused by Penicillium marneffei: description of first natural infection in man. , 1973, American journal of clinical pathology.

[123]  R. Lehrer,et al.  Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. , 1969, The Journal of clinical investigation.

[124]  G. Ségretain [Penicillium marneffei n.sp., agent of a mycosis of the reticuloendothelial system]. , 1959, Mycopathologia et mycologia applicata.

[125]  P. Sureau,et al.  [Penicillosis from Rhizomys sinensis]. , 1956, Bulletin de la Societe de pathologie exotique et de ses filiales.

[126]  A. Chaiprasert,et al.  Penicillium marneffei: types and drug susceptibility , 2004, Mycopathologia.

[127]  F. Dromer,et al.  Antifungal drug resistance in pathogenic fungi. , 1998, Medical mycology.

[128]  T. Sirisanthana,et al.  Infection due to Penicillium marneffei. , 1997, Annals of the Academy of Medicine, Singapore.